Emyria Ltd (ASX:EMD) Michael Winlo tells Proactive the company has been accepted into the US National Institute of Health’s (NIH) Preclinical Screening Platform for Pain program. The NIH’s National Institute of Neurological Disorders and Stroke (NINDS) � also the leading funder of neurological research in the US will run the study as part of a broader initiative to stem the opioid public health crisis.
Hashtag: #Emyria
The issuer is solely responsible for the content of this announcement.
PRINCETON, N.J.--(BUSINESS WIRE)--Verdantis, a pioneering leader in AI-powered data solutions, proudly announces the appointment of…
Providing Exclusive and Unique Experiences to Indonesian Tourists MACAU SAR - Media OutReach Newswire -…
SEOUL, South Korea--(BUSINESS WIRE)--Leading semiconductor company SK hynix today announced that its stick-type SSD, the…
LONDON--(BUSINESS WIRE)--NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have officially entered into a dynamic…
GUILFORD, Conn. & SHANGHAI--(BUSINESS WIRE)--Drug Farm announced today the U.S. Food and Drug Administration (FDA)…
Unveiling Groundbreaking Research and Product Development to Reduce Antibiotic Use in Digestive and Respiratory Care…